Patient recruitment is underway for a first-of-its-kind clinical trial that will use Tilray study drugs to determine the efficacy of medical cannabis for the prevention of chemotherapy-induced nausea and vomiting.
The trial, which was announced in February, is a partnership between Tilray, the New South Wales Government, the University of Sydney, and Chris O'Brien Lifehouse, a world-class cancer treatment center and hospital in New South Wales.
Tilray is providing a proprietary capsule formulation for the trial, which will allow researchers to test an investigational product containing equal amounts of two cannabinoids (chemical compounds): cannabidiol (CBD) and tetrahydrocannabinol (THC). The trial is being led by an interdisciplinary group of researchers with expertise in oncology and cannabinoids.
CINV is one of the most distressing acute side effects of cancer treatment. It occurs in up to 80% of patients and can have a significant impact on quality of life. Many patients do not experience relief of their symptoms with the current drugs on the market or find that these drugs are too limited in their availability.
More information about the trial, including information regarding recruitment and fact sheets for patients and physicians, is available on the webpage of the New South Wales Government.